NNO2 Stock Overview
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Novo Nordisk A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 96.26 |
| 52 Week High | DKK 137.98 |
| 52 Week Low | DKK 87.25 |
| Beta | 0.16 |
| 11 Month Change | -11.25% |
| 3 Month Change | -21.02% |
| 1 Year Change | 3.29% |
| 33 Year Change | 92.89% |
| 5 Year Change | 278.23% |
| Change since IPO | 385.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNO2 | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -6.8% | -3.3% | 0.9% |
| 1Y | 3.3% | 3.5% | 1.5% |
Return vs Industry: NNO2 underperformed the Austrian Pharmaceuticals industry which returned 3.5% over the past year.
Return vs Market: NNO2 matched the Austrian Market which returned 1.5% over the past year.
Price Volatility
| NNO2 volatility | |
|---|---|
| NNO2 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: NNO2 has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: NNO2's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 71,880 | Lars Jorgensen | www.novonordisk.com |
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
Novo Nordisk A/S Fundamentals Summary
| NNO2 fundamental statistics | |
|---|---|
| Market cap | €422.37b |
| Earnings (TTM) | €12.70b |
| Revenue (TTM) | €36.27b |
33.3x
P/E Ratio11.6x
P/S RatioIs NNO2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNO2 income statement (TTM) | |
|---|---|
| Revenue | DKK 270.58b |
| Cost of Revenue | DKK 41.51b |
| Gross Profit | DKK 229.07b |
| Other Expenses | DKK 134.35b |
| Earnings | DKK 94.72b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 21.38 |
| Gross Margin | 84.66% |
| Net Profit Margin | 35.01% |
| Debt/Equity Ratio | 47.3% |
How did NNO2 perform over the long term?
See historical performance and comparison